Astellas Pharma’s Vernakalant For Atrial Fibrillation Goes Before FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Cardiovascular and Renal Drugs Advisory Committee considers Astellas’ NDA re-submission for the indication Dec. 11.
You may also be interested in...
Dosing Schedule For Solvay’s Pulzium Will Be Addressed During Cardio-Renal Meeting
FDA’s Cardiovascular and Renal Drugs Advisory Committee also will weigh whether tedisamil should be approved with risk management plan proposed by Solvay.
Dosing Schedule For Solvay’s Pulzium Will Be Addressed During Cardio-Renal Meeting
FDA’s Cardiovascular and Renal Drugs Advisory Committee also will weigh whether tedisamil should be approved with risk management plan proposed by Solvay.
FDA Advisory Committee Meeting Planned To Review Atrial Fibrillation Drugs
Safety and efficacy of Cardiome/Astellas’ vernakalant and Solvay’s tedisamil will be debated during the Dec. 11-12 meeting, according to Cardiome.